Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

30
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
30
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

20
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
20
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

19
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this...
19
The Blood-brain Barrier00:49

The Blood-brain Barrier

47.3K
Overview
47.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and therapeutic delivery of microRNAs targeting deregulated glioblastoma pathways inhibits tumor growth in mice.

The Journal of clinical investigation·2026
Same author

Microenvironment T-Type calcium channels regulate neuronal and glial processes in tumor cells to promote glioblastoma growth.

Neuro-oncology·2026
Same author

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

AJNR. American journal of neuroradiology·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: May 2, 2026

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

9.4K

Thrombosis in brain tumors.

Jasmin T Jo1, David Schiff2, James R Perry3

  • 1Division of Neuro-Oncology, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts.

Seminars in Thrombosis and Hemostasis
|March 7, 2014
PubMed
Summary

Venous thromboembolism (VTE) is common in brain tumor patients, linked to tissue factor (TF). While anticoagulation is safe for treatment, routine VTE prevention is not yet supported by data.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.4K

Related Experiment Videos

Last Updated: May 2, 2026

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

9.4K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.4K

Area of Science:

  • Neuro-oncology
  • Hematology
  • Oncology

Background:

  • Venous thromboembolism (VTE) affects up to 30% of brain tumor patients, with risk increasing with malignancy grade.
  • Tissue factor (TF) production is a key driver of VTE in these patients, influencing both coagulation and cancer progression.
  • Managing VTE in brain tumor patients is challenging due to the risk of intracranial hemorrhage with anticoagulants.

Purpose of the Study:

  • To review current anticoagulation strategies for established VTE in brain tumor patients.
  • To discuss the safety and efficacy of anticoagulants, including heparin, LMWH, and warfarin.
  • To evaluate the potential role of novel oral anticoagulants and thromboprophylaxis in this population.

Main Methods:

  • Review of literature on VTE in brain tumor patients.
  • Discussion of established anticoagulant therapies (heparin, LMWH, warfarin).
  • Evaluation of emerging anticoagulants and thromboprophylaxis strategies.

Main Results:

  • Therapeutic anticoagulation, especially LMWH followed by prophylaxis, is generally safe and effective for VTE treatment, even with antiangiogenic agents.
  • Anticoagulation can reduce perioperative VTE risk.
  • Current data do not support routine thromboprophylaxis for brain tumor patients.

Conclusions:

  • Anticoagulation is crucial for treating VTE in brain tumor patients, with LMWH being a preferred option.
  • Further research is needed on hypercoagulable state mechanisms and biomarkers for risk stratification.
  • Novel oral anticoagulants are not currently recommended for cancer-related VTE due to limited data.